

(19)



Europäisch s Pat ntamt
Europ an Patent Office
Office européen des br vets



(11)

EP 0 887 416 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
30.12.1998 Bulletin 1998/53

(51) Int Cl.⁶: C12N 15/57, C12N 9/64,
C12N 1/21, C12N 5/10,
C07K 16/40, C12Q 1/37,
C12N 15/11, C12Q 1/68

(21) Application number: 98304827.3

(22) Date of filing: 18.06.1998

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 24.06.1997 EP 97304440
12.02.1998 US 22699

(71) Applicants:
• SMITHKLINE BEECHAM CORPORATION
Philadelphia Pennsylvania 19103 (US)
• SMITHKLINE BEECHAM PLC
Brentford, Middlesex TW8 9EP (GB)

(72) Inventors:
• Kikly, Kristine, SmithKline Beecham Pharm.
King of Prussia, Pennsylvania 19406 (US)
• Knab, Anne, SmithKline Beecham Pharm.
King of Prussia, Pennsylvania 19406 (US)
• Southan, Christopher, SmithKline Beecham Plc.
Brentford, Middlesex TW8 9EP (GB)

(74) Representative: Crump, Julian Richard John et al
FJ Cleveland,
40-43 Chancery Lane
London WC2A 1JQ (GB)

(54) **Human AFC1**

(57) The hAFC1 polypeptides and polynucleotides
and methods for producing such polypeptides by recom-

binant techniques are disclosed. Also disclosed are
methods for utilizing hAFC1 polypeptides and polynu-
cleotides in therapy, and diagnostic assays for such.

EP 0 887 416 A2

Description

This application claims the benefit of U.K. Application No. 97304440.7, filed June 24, 1997, which is herein incorporated by reference in its entirety.

Field of the Invention

This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

Background of the Invention

The drug discovery process is currently undergoing a fundamental revolution as it embraces 'functional genomics', that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on 'positional cloning'. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

Summary of the Invention

The present invention relates to hAFCI, in particular hAFCI polypeptides and hAFCI polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of cancer, inflammation, autoimmunity, allergy, asthma, rheumatoid arthritis, CNS inflammation, cerebellar degeneration, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, head injury damage, and other neurological abnormalities, septic shock, sepsis, stroke, osteoporosis, osteoarthritis, ischemia reperfusion injury, cardiovascular disease, kidney disease, liver disease, ischemic injury, myocardial infarction, hypotension, hypertension, AIDS, myelodysplastic syndromes and other hematologic abnormalities, aplastic anemia, male pattern baldness, and bacterial, fungal, protozoan and viral infections, hereinafter referred to as "the Diseases", amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with hAFCI imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate hAFCI activity or levels.

Description of the Invention

In a first aspect, the present invention relates to hAFCI polypeptides. Such peptides include isolated polypeptides comprising an amino acid sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

Further peptides of the present invention include isolated polypeptides in which the amino acid sequence has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2.

Further peptides of the present invention include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:1.

Polypeptides of the present invention are believed to be members of the metalloprotease family of polypeptides. They are therefore of interest because prenylation is critical to the functional activity of a wide variety of nuclear and cellular proteins. This modification involves the post-translational attachment of isoprenoid groups (e.g., farnesyl or geranylgeranyl) to a cysteine near the C-terminus of a protein. This attachment is invariably followed by proteolytic removal of the three C-terminal residues and the esterification of a methyl group at the C-terminus. Therapeutically, one of the more intensely studied prenylated proteins is ras. Mutated ras genes are frequently found in a variety of tumors. Localization of the processed protein to the plasma membrane via prenylation is necessary for its transforming ability. Accordingly, inhibition of the ras farnesylation step has been the subject of concerted investigation. Several inhibitors of ras farnesyltransferase (FPTase) have been developed and have shown potential as chemotherapeutic agents in

animal models. However, this success has not been replicated in many human tumor xenografts, perhaps because Ki-ras can be prenylated with either a farnesyl or geranylgeranyl group.

Recently, two genes in *Saccharomyces cerevisiae* were identified that appear to be responsible for the second step in prenylation processing, the proteolytic removal of the last three amino acids from the C-terminus (Boyartchuk, et al. (1997) Science, 275:1796-1800). The identity and role of these proteases has heretofore remained unknown, although an endoproteolytic activity that cleaves the terminal tripeptide from prenylated substrates had been identified in yeast, mammalian, and *Xenopus* cells.

AFC 1 was identified as an integral membrane protease with a metalloprotease sequence motif essential for its activity. It was responsible for the majority of α -factor mating pheromone precursor processing *in vivo*. Thus, this family of prenyl protein proteases offers an alternate and potentially better target for cancer therapeutic intervention than the prenyltransferases.

In Alzheimer's disease (AD) the affected brain is characterized by numerous amyloid plaques, neurofibrillary tangles, and neuronal losses. The amyloid is composed of amyloid beta peptides (A-beta), 40-43 amino acid fragments of large membrane protein, amyloid precursor protein (APP). This precursor is cleaved by proteolytic enzyme, beta, and gamma secretase yielding N and C terminus of the A-beta.

Considerable effort has been directed to identify these enzymes, particularly as inhibition of the gamma secretase could reduce the amount of A-beta 42 being produced from the metabolism of the amyloid protein precursor. It was established that missense mutations in the genes encoding APP, presenilin1, and presenilin2, all lead to increased production of A-beta 42 and the early deposition of this peptide is an important event in the pathogenesis of AD.

Recent evidence (Haass and Selkoe, Nature 391, 339-340, 1998 and refs. therein) implicates the endoplasmic reticulum (ER) membrane as the site of gamma secretase activity. Because of the transmembrane architecture of the hAFC1 protein, it is a candidate to be the gamma secretase. Inhibition of this protease therefore offers a good drug target for the therapeutic intervention for AD. These properties are hereinafter referred to as "hAFC1 activity" or "hAFC1 polypeptide activity" or "biological activity of hAFC1". Also included amongst these activities are antigenic and immunogenic activities of said hAFC1 polypeptides, in particular the antigenic and immunogenic activities of the polypeptide of SEQ ID NO:2. Preferably, a polypeptide of the present invention exhibits at least one biological activity of hAFC1.

The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to hAFC1 polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 encoding the polypeptide of SEQ ID NO:2.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, to SEQ ID NO:1 over the entire length of SEQ ID NO:1. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 as well as the polynucleotide of SEQ ID NO:1.

The invention also provides polynucleotides which are complementary to all the above described polynucleotides.

The nucleotide sequence of SEQ ID NO:1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 34 to 1458) encoding a polypeptide of 474 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO:1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of the SEQ ID NO:2 is structurally related to other proteins of the metalloprotease family, having homology and/or structural similarity with yeast AFC1.

Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one hAFC1 activity.

The present invention also relates to partial or other polynucleotide and polypeptide sequences which were first identified prior to the determination of the corresponding full length sequences of SEQ ID NO:1 and SEQ ID NO:2.

Accordingly, in a further aspect, the present invention provides for an isolated polynucleotide comprising:

(a) a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;

(b) a nucleotide sequence which has at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to SEQ ID NO:1 over the entire length of SEQ ID NO:3; or

(c) the polynucleotide of SEQ ID NO:3.

The present invention further provides for a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

The nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded thereby are derived from EST (Expressed Sequence Tag) sequences. It is recognised by those skilled in the art that there will inevitably be some nucleotide sequence reading errors in EST sequences (see Adams, M.D. *et al.*, Nature 377 (supp) 3, 1995). Accordingly, the nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded therefrom are therefore subject to the same inherent limitations in sequence accuracy. Furthermore, the peptide sequence encoded by SEQ ID NO:3 comprises a region of identity or close homology and/or close structural similarity (for example a conservative amino acid difference) with the closest homologous or structurally similar protein.

Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human fetal liver, using the expressed sequence tag (EST) analysis (Adams, M.D., *et al.* Science (1991) 252:1651-1656; Adams, M.D. *et al.*, Nature, (1992) 355:632-634; Adams, M.D., *et al.*, Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Further embodiments of the present invention include polynucleotides encoding polypeptide variants which comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 5 to 10, 1 to 5, 1 to 3, 1 to 2 or 1, amino acid residues are substituted, deleted or added, in any combination.

Polynucleotides which are identical or sufficiently identical to a nucleotide sequence contained in SEQ ID NO:1, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding homologs and orthologs from species other than human) that have a high sequence similarity to SEQ ID NO:1. Typically these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% identical, most preferably 95% identical to that of the referent. The probes or primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species

other than human, may be obtained by a process which comprises the steps of screening an appropriate library under stringent-hybridization-conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1x SSC at about 65°C. Thus the present invention also includes polynucleotides obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is cut short at the 5' end of the cDNA. This is a consequence of reverse transcriptase, an enzyme with inherently low 'processivity' (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during 1st strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the 'missing' 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems which comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989). Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *streptococci*, *staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL (*supra*). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the

screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO:1 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled hAFC1 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, e.g., Myers *et al.*, *Science* (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, *Proc Natl Acad Sci USA* (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotide probes comprising hAFC1 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, *Science*, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the hAFC1 gene by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly cancer, inflammation, autoimmunity, allergy, asthma, rheumatoid arthritis, CNS inflammation, cerebellar degeneration, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, head injury damage, and other neurological abnormalities, septic shock, sepsis, stroke, osteoporosis, osteoarthritis, ischemia reperfusion injury, cardiovascular disease, kidney disease, liver disease, ischemic injury, myocardial infarction, hypotension, hypertension, AIDS, myelodysplastic syndromes and other hematologic abnormalities, aplastic anemia, male pattern baldness, and bacterial, fungal, protozoan and viral infections, amongst others.

The nucleotide sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data

are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University-Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes).

The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

Antibodies against polypeptides of the present invention may also be employed to treat the Diseases, amongst others.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response to protect said animal from the Diseases hereinbefore mentioned, amongst others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering a polypeptide of the present invention *via* a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases.

A further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a polypeptide of the present invention wherein the composition comprises a polypeptide or polynucleotide of the present invention. The vaccine formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention are responsible for many biological functions, including many disease states, in particular the Diseases hereinbefore mentioned. It is therefore desirable to devise screening methods to identify compounds which stimulate or which inhibit the function of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate or which inhibit the function of the polypeptide. In general, agonists or antagonists may be employed for therapeutic and prophylactic purposes for

such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists, antagonists or inhibitors so identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, *Current Protocols in Immunology* 1(2): Chapter 5 (1991)).

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring hAFCI activity in the mixture, and comparing the hAFCI activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and hAFCI polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, *J Mol Recognition*, 8:52-58 (1995); and K. Johanson *et al.*, *J Biol Chem*, 270(16):9459-9471 (1995)).

Another aspect of the invention is a method for assaying a medium for the presence of a substance that modulates hAFCI protein function by inhibiting its proteolytic activity on prenylated substrates or APP. Examples of modulators include, but are not limited to peptides and small organic molecules including peptidomimetics. These can be in solution or attached to solid-phase supports. Cellular substrates can include prenylated substrates or APP or fragments thereof together with synthetic analogs thereof. The mixture is incubated with a test substance which is suspected of inhibiting hAFCI under conditions which permit the formation of an enzyme/substrate complex and subsequent cleavage of the substrate. Any inhibitors so identified would be expected to be useful as a therapeutic for the treatment and prevention of cancer and/or neurodegeneration including FAD and AD.

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of potential polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which decrease or enhance the production of such polypeptides, which comprises:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- (c) a cell membrane expressing a polypeptide of the present invention; or
- (d) antibody to a polypeptide of the present invention;

which polypeptide is preferably that of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist, antagonist or inhibitor of the polypeptide, by:

- (a) determining in the first instance the three-dimensional structure of the polypeptide;
- ~~(b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist, antagonist or inhibitor;~~
- (c) synthesizing candidate compounds that are predicted to bind to or react with the deduced binding or active site; and
- (d) testing whether the candidate compounds are indeed agonists, antagonists or inhibitors. It will be further appreciated that this will normally be an iterative process.

In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, cancer, inflammation, autoimmunity, allergy, asthma, rheumatoid arthritis, CNS inflammation, cerebellar degeneration, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, head injury damage, and other neurological abnormalities, septic shock, sepsis, stroke, osteoporosis, osteoarthritis, ischemia reperfusion injury, cardiovascular disease, kidney disease, liver disease, ischemic injury, myocardial infarction, hypotension, hypertension, AIDS, myelodysplastic syndromes and other hematologic abnormalities, aplastic anemia, male pattern baldness, and bacterial, fungal, protozoan and viral infections, related to either an excess of, or an under-expression of, hAFC1 polypeptide activity.

If the activity of the polypeptide is in excess, several approaches are available. One approach comprises administering to a subject in need thereof an inhibitor compound (antagonist) as hereinabove described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function of the polypeptide, such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the hAFC1 polypeptide.

In still another approach, expression of the gene encoding endogenous hAFC1 polypeptide can be inhibited using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or separately administered (see, for example, O'Connor, *J Neurochem* (1991) 56:560 in *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988)). Alternatively, oligonucleotides which form triple helices with the gene can be supplied (see, for example, Lee *et al.*, *Nucleic Acids Res* (1979) 6:3073; Cooney *et al.*, *Science* (1988) 241:456; Dervan *et al.*, *Science* (1991) 251:1360). These oligomers can be administered *per se* or the relevant oligomers can be expressed *in vivo*.

For treating abnormal conditions related to an under-expression of hAFC1 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of hAFC1 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, *Gene Therapy and other Molecular Genetic-based Therapeutic Approaches*, (and references cited therein) in *Human Molecular Genetics*, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide, such as the soluble form of a polypeptide of the present invention, agonist/antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical

and/or localized, in the form of salves, pastes, gels, and the like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 µg/kg of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

Polynucleotide and polypeptide sequences form a valuable information resource with which to identify further sequences of similar homology. This is most easily facilitated by storing the sequence in a computer readable medium and then using the stored data to search a sequence database using well known searching tools, such as GCC. Accordingly, in a further aspect, the present invention provides for a computer readable medium having stored thereon a polynucleotide comprising the sequence of SEQ ID NO:1 and/or a polypeptide sequence encoded thereby.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxynucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single- stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein

cofactors", *Meth Enzymol* (1990) 182:626-646 and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann-NY-Acad-Sci* (1992)-663:48-62).

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity" is a measure of the identity of nucleotide sequences or amino acid sequences. In general, the sequences are aligned so that the highest order match is obtained. "Identity" *per se* has an art-recognized meaning and can be calculated using published techniques (see, e.g.: COMPUTATIONAL MOLECULAR BIOLOGY, Lesk, A.M., ed., Oxford University Press, New York, 1988; BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, Smith, D.W., ed., Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there exist a number of methods to measure identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to skilled artisans (Carillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego, 1994, and Carillo, H., and Lipton, D., *SIAM J Applied Math* (1988) 48:1073. Methods to determine identity and similarity are codified in computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., *et al.*, *Nucleic Acids Research* (1984) 12(1):387), BLASTP, BLASTN, and FASTA (Atschul, S.F. *et al.*, *J Molec Biol* (1990) 215:403).

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein n_n is the number of nucleotide alterations, x_n is the total number of nucleotides in SEQ ID NO:1, and y is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \cdot y),$$

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2, and y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

SEQUENCE INFORMATION

SEQ ID NO:1

5 CGCGGCTGAAGGAGCCGGCGGAACCGGGTGGCCATGGGGATGTGGGCATCGCTGGACGCTTTGTGGGAGATG
CCGGCCGAGAAGCGTATCTTCGGGGCCGTGCTGCTCTTTTCTGGACAGTGTATCTTTGGGAGACCTTCCTA
GCACAGCGGCAGAGAAGGATATATAAAACAACAACCTCATGTACCACCGGAGTTAGGACAGATCATGGATTCT
10 GAAACATTTGAGAAATCTCGACTCTATCAACTGGATAAAAGCACTTTCAGCTTCTGGTCAGGACTCTATTCA
GAGACTGAAGGCACTCTTATTCTTCTCTTTGGAGGAATACCTTATCTCTGGAGACTTCTGGACGGTTCTGT
GGTTATGCTGGCTTTGGACCAGAATATGAGATCACTCAGTCCCTGGTGTCTCTGCTGTTGGCTACACTTTTC
AGTGCAATTGACTGGTTTGGCATGGAGTCTTTATAATACTTTTGTGATAGAAGAAAAACATGGCTTCAATCAA
15 CAGACTTTGGGGTCTTCATGAGAGATGCAATCAAGAAATTTGTTGTGACTCAGTGTATTTTGTTCCTGTG
TCTTCACTTCTACTTTACATTATTAAATTTGGGGGTGACTATTTTTTTATTTATGCTGGCTGTTACATTA
GTTGTGTCTCTGGTTCTTGTCAATCTATGCTGATTATATTGCCCTTTATTTGACAAATTCACACCTCTG
CCTGAGGGAAAGCTTAAAGAAGAAATTGAAGTAATGGCAAAGAGTATTGACTTTCCTTTGACGAAGGTGTAT
20 GTTGTGGAAGGATCTAAACGCTCTTCCACAGCAATGCTTATTTTATGGCTTCTTCAAGAACAAGCGAATA
GTTTTGTTTGACACTCTACTAGAAGAGTACTCTGTACTAAACAAAGACATCCAGGAGGATTCTGGCATGGAA
CCCCGCAATGAGGAAGAAGGGAACAGTGAAGAAATAAAAGCTAAAGTTAAAAATAAGAAACAAGGATGTAAA
AATGAAGAGGTACTCGCTGTACTAGGCCATGAAGTGGGGCACTGGAAGTGGGACATACAGTCAAAAATATCA
25 TTATTAGCCAGAGAATTCTTCTGTGTTTTTTTTTATTTGCTGTATTAATTGGTCGAAAGGAGCTTTTTGCT
GCATTTGGTTTTTATGATAGCCAACCCACTCTTATTGGACTATTGATCATCTTCCAGTTTATTTTTTACCT
TACAATGAGGTCTTTCTTTTTGCCTAACAGTCCTAAGCCGAGATTTGAGTTTCAAGCTGATGCATTTGCC
30 AAGAACTTGGAAGGCTAAAGACTTATATTCTGCTTTAATCAAACCTTAACAAAGATAACTTGGGATTCCCT
GTTTCTGACTGGTTGTTCTCAATGTGGCATTATTCTCATCTCCACTGCTAGAGAGACTTCAAGCTTTGAAA
ACTATGAAGCAACACTGAGATGTCCAGGATCTGTGACTGAAGACATTTCTGATTATTTCTGTCTTGGCAGCA
TGTTCCAGCTCTTGATGTTTTTAACTTTTTTTAGAAAGAAAATTAAGTACAGAAAAGCCAGATTTAAAT
35 ACATTTAATATGTCATTTTAAAAATGATTTTAAATAATTCATTTCTTAAACACTGAATGAATTTTGAAGCTT
AATGTTTTTAAAGGCATAGTTTTATCTTTGACATCTAATTTACCATCAAGTTGTAAAATTATTTGGAAAAAT
ACAGAACTCGTTTTATTTGTATACTTATATGGAATCTGCATGTGAGGTGTTTGGGGCATATGTTTGAAAGA
40 GGGAGCATCACCACAGGAATCCTTTCTGTGAGGTGGAACAGTGGTCCTGAATCATTGTGCTCACACCTAAC
TTGAAATCTGGTCTTACTTTTCATGCTGTTATGATTTACCTGGTGAATCAGTGTTTTAAATAAGAAAGGTAA
TAGTTGGTAAGGCCAATGTTATTTAAATGAAAGTAGTTAGAAAAATGCTCTCTTATTCTACCAATTTTTTAA
TTTCTTTCTTCCCTTTCTTGCTACACAGTGATCAAGAGTTTCTCATAGTGCTTTGAAGTTAGAAATTATGTA
45 TAGGATATTTTAAATCATTGAGTTTTGTGGGGTTTTTTTGTGTTGTTGTTTCTTTTGTGTTTTTGGAAAATCC
GTGTCTTTATCTTTTTTTCCACGTGGTAGATATGATCCCATTTGGAGGTAAATTGTAGCTTCTTCTCATTCA
TGCAGTAAATAATACATCCTTTCACTCAGCAGAGATGGCCATATTAAACACGTTTTGCTATGTTAAAAGTGG
50 CAGAACAGGAAAGACGAATTAAAAATAACATTTTTTAAGCGACATAAGGATGAAATACTGATGAATCTCTGT
GACATTACAGGGAAAAAATATAGTTTTCTATCTCTTTCAAGGGCAGAAGAGTTTTTCATTTTTATTTTGTGA
ATTTTATCTGTAAGTCATAAATATTACTTAATCAGGCCTGATTCTACTTTTGAATAATACAGTTCTTGAAAT
GCAGATAATGTTTACTTTGAAAACAAATGTCATGAATGATTTCCAGTTTTTAAAGCTATATGTTTCACTGCT
55 TCATATCTCTGTCCACTTTCTGAATGAGAACTTATTTTGTGCCTAGAGCTCTCACTCACTGATAATGCTTAT

TACCTTCTGGGCATTTATTCCAAAGTGGGATCAACTGTACGCCTTTGGTATCTGACCATAAAGTCTTTTGCT
 CCGCTGACATTTGGGTGATGTCTTCACATGGAAATATAATAAAAAATAAAAACTAGTTTAATACTGCATTAT
 5 TTATTTTCCTAAGGCTAAAGAGGAGCAGTCCCTATGCTTTTATTAGCATCCTTTATCTGTGACTTCATGCTC
 TGATAACTGCCTTTCCTTCCTTCTGTGCCTTTGAATACAAATTTAGTTCTGCAAAAGTGAAACATTAAACA
 TTGCCAACGCAAATGT

SEQ ID NO:2

MGMWASLDALWEMPAEKRIFGAVLLFSWTVYLWETFLAQRQRRIYKTTTHVPELQIMDSETFEKSRLYQL
 DKSTFSFWSGLYSETEGLTILLFGGIPYLWRLSGRFCGYAGFGPEYEITQSLVFLLLATLFSALTGLPWSLY
 15 NTFVIEEKHGFNQTLGFFMRDAIKKFVVTQCILLPVSSLLLYIIKIGGDYFFIYAWLFTLVVSLVLVTIYA
 DYIAPLFDKFTPLPEGKLEEEIEVMAKSIDFPLTKVYVEGSKRSSHSNAYFYGFFKNKRIVLFDTLLEEYS
 VLNKDIQEDSGMEPRNEEEGNSEEIKAKVKNKKQGCKNEEVLAVLGHELGHKWDIQSKIISLLAREFFPVFF
 LFAVLIGRKELFAAFGYDSQPTLIGLLIIQFIFSPYNEVLSFCLTVLSRRFEFQADAFKLGKAKDLYS
 20 ALIKLNKDNLGFVSDWLFMSMWHYSHPPLLERLQALKTMKQH

SEQ ID NO:3

AGAAATTGAAGTAATGGCAAAGAGTATTGACTTTCCTTTGACGAAGGTGTATGTTGTGGA
 25 AGGNTCTAAACGCTCTTCCCACAGCAATGCTTATTTTTATGGCTTCTTCAAGAACAAGCG
 AATAGTTTTGTTTGACACTCTACTAGAAGAGTACTCTGTACTAAACAAAGACATCCAGGA
 GGATTCTGGCATGGAACCCCGCAATGAGGAAGAAGGGAACAGTGAAGAAATAAAAGCTAA
 AGTTAAAAATAAGAAACAAGGATGTAAAAATGAGGAGGTACTCGCTGTACTAGGCCATGA
 ACTGGGGCACTGGAAGTTGGGACATACAGTCAAAAATATCATTATTAGCCAGATGAATTC
 30 TTTCTGTGTTTTTTTTTATTTGCTGTATTAATTGGTCGAAAGGAGCTTTTGTCTGCATT
 TGGTTTTATGATAGCCAACCCACTCTTATTGGACTATTGATCATCTCCAGTTTATTTT
 TTCACCTTACAATGAGGTTCTTTCTTTTGGCCTAACAGTCTTAAGCCGCAGATTGAGTT
 TCAAGCTGATGCATTTTGCCAAGAACTTGGGAAGGCTAAAGACTTATATTCTGCTTTAAT
 CAAACTTAACAAAGATAACTTGGGATTCCCTGTTTCTGACTGGTTGTTCTCAATGTGGCA
 35 TTATTCTCATCTCCACTGCTAGAGAGACTTCAAGCTTTGAAAATATGAAGCAACACTG
 AGATGTCCAGGATCTGTGACTGAAGACATTTCTGATTATTCTGTCTGCGCAGCATGTTT
 CAGCTCTTGATGTTTTTAACTTTTTTTTAGAAGAAAAATTAAGTACAGAAAAGCCCAGA
 TTTAAATACATTTAATATGTCAATTTTAAATGATTTTAATAATTCAATTTCTTAAACAC
 TGAATGAATTTTGAAGCTTAATGTTTTTAAAGGCATAGTTTATCTTTGACATCTAATTT
 40 ACCATCAAGTTGTAAATTTATTTGAAAAATACAGAACTCGTTTATTTGTATACTTATA
 TGGAAATCTGCATGTGAGGTGTTTGAGGGCATATGTTTGAAAGAGGGAGCATCACCACAGG
 AATCCCTTTCTGTGAGGTGGAACAGTGGTCTGAATCATTGTGCTCACACCTAACTTGA
 AATCTGGTCTTACTTTTCATGCTGTTATGATTTGACCTGGTGAATCAGTGTTTTAAATAAG
 AAAGGTAATAGTTGGTAAGGCCAATGTTATTTAAATGAAAGTAGTTAGAAAAATGCTCTC
 45 CTATTCTACCAAATTTTAAATTTCTTCTTCCCTTTCTTGCTACACAGTGATCAAGAGTT
 TCTCATAGTGCTTTGAAGTTAGAAATTATGTATAGGATATTTTAAATCATTGAGTTTTGT
 GGGGTTTTTTGTTTGTGTTGTTTCTTTGTTTTTTGGAAATCCGTGTCTTTATCTTTTT
 TTCCCACGTGGTAGATATGATCCCATTGGAGGTAAATTGTAGCTTCTTCTCATTTCATGCA
 GTAAATAATACATCCTTTCACTCAGCAGAGATGGCCATATTAACACGTTTTTGCTATGTT
 50 AAAAGTGGCAGAACAGGAAGACGAATTAATAATAACATTTTTTAAGCGACATAAGGATG
 AAATACTGATGAATCTCTGTGACATTACAGGGAAAAAATATAGTTTTCTATCTCTTTCA
 AGGGCAGAAGAGTTTTTCAATTTTTTGTAAATTTTATCTGTAAGTCATAAATATTACT
 TAATCAGGCCTGATTCTACTTTTGAATTTACAGTTCTTGAAATGCAGATAATGTTTACT
 TTGAAAACAAATGTCATGAATGATTTCCAGTTTTTAAAGCTATATGTTTCACTGCTTCCA
 55 TATCTCTGGTCCACTTTCTGGATGGAGAACNTAATTTGGTGCCNAGAGCTCTCACTCACG
 GATAAGGCTAATNACCTCCGGGGCATTATTTCCAGTGGGGTCACTGTACGCCTTAGGG
 ATCTGACCATAAGTCTTTGGCCCGCGAAATTGGGGGAGGCTCCAGGGAAAAANT

Ann x to th description

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: SmithKline Beecham Corporation & SmithKline
Beecham Plc

(ii) TITLE OF THE INVENTION: Human AFC1

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: SmithKline Beecham, Corporate Intellectual
Property

(B) STREET: Two New Horizons Court

(C) CITY: Brentford

(D) STATE: Middlesex

(E) COUNTRY: United Kingdom

(F) ZIP: TW8 9EP

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette

(B) COMPUTER: IBM Compatible

(C) OPERATING SYSTEM: DOS

(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: TO BE ASSIGNED

(B) FILING DATE: 12-FEB-1998

(C) CLASSIFICATION: UNKNOWN

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: UK Application No. 97304440.7

(B) FILING DATE: 24-JUNE-1997

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: CONNELL, Anthony Christopher

(B) REGISTRATION NUMBER: 5630 & 26758

(C) REFERENCE/DOCKET NUMBER: GH-30404

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: +44 1279 644 395

(B) TELEFAX: +44 181 975 6294

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2968 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CGCGGCTGAA	GGAGCCGGCG	GAACCGGGTG	GCCATGGGGA	TGTGGGCATC	GCTGGACGCT	60
TTGTGGGAGA	TGCCGGCCGA	GAAGCGTATC	TCGGGGGCCG	TGCTGCTCTT	TTCTGGACA	120
GTGTATCTTT	GGGAGACCTT	CCTAGCACAG	CGGCAGAGAA	GGATATATAA	AACAACAAC	180
CATGTACCAC	CGAGTTAGG	ACAGATCATG	GATTCTGAAA	CATTTGAGAA	ATCTCGACTC	240
TATCAACTGG	ATAAAAGCAC	TTTCAGCTTC	TGGTCAGGAC	TCTATTTCAGA	GACTGAAGGC	300
ACTCTTATTC	TTCTCTTTGG	AGGAATACCT	TATCTCTGGA	GACTTTCCTG	ACGGTTCCTG	360
GGTTATGCTG	GCTTTGGACC	AGAATATGAG	ATCACTCAGT	CCCTGGTGTT	TCTGCTGTTG	420
GCTACACTTT	TCAGTGCAAT	GACTGGTTTG	CCATGGAGTC	TTTATAATAC	TTTTGTGATA	480
GAAGAAAAAC	ATGGCTTCAA	TCAACAGACT	TTGGGGTTCT	TCATGAGAGA	TGCAATCAAG	540
AAATTTGTTG	TGACTCAGTG	TATTTTGTTG	CCTGTGTCTT	CACTTCTACT	TTACATTATT	600
AAAATTGGGG	GTGACTATTT	TTTTATTAT	GCCTGGCTGT	TCACATTAGT	TGTGTCTCTG	660
GTTCTTGTCA	CAATCTATGC	TGATTATATT	GCCCCTTTAT	TTGACAAATT	CACACCTCTG	720
CCTGAGGGAA	AGCTTAAAGA	AGAAATTGAA	GTAATGGCAA	AGAGTATTGA	CTTTCCTTTG	780
ACGAAGGTGT	ATGTTGTGGA	AGGATCTAAA	CGCTCTTCCC	ACAGCAATGC	TTATTTTTAT	840
GGCTTCTTCA	AGAACAAGCG	AATAGTTTTG	TTTGACACTC	TACTAGAAGA	GTACTCTGTA	900
CTAAACAAAG	ACATCCAGGA	GGATTCTGGC	ATGGAACCCC	GCAATGAGGA	AGAAGGGAAC	960
AGTGAAGAAA	TAAAAGCTAA	AGTTAAAAAT	AAGAAACAAG	GATGTAAAAA	TGAAGAGGTA	1020
CTCGCTGTAC	TAGGCCATGA	ACTGGGGCAC	TGGAAGTGGG	ACATACAGTC	AAAAATATCA	1080
TTATTAGCCA	GAGAATTCTT	TCCTGTGTTT	TTTTTATTTG	CTGTATTAA	TGGTCGAAAG	1140
GAGCTTTTTG	CTGCATTTGG	TTTTTATGAT	AGCCAACCCA	CTCTTATTGG	ACTATTGATC	1200
ATCTTCCAGT	TTATTTTTTC	ACCTTACAAT	GAGGTTCTTT	CTTTTTGCCT	AACAGTCCTA	1260
AGCCGCAGAT	TTGAGTTTCA	AGCTGATGCA	TTTGCCAAGA	AACTTGGGAA	GGCTAAAGAC	1320
TTATATTCTG	CTTAAATCAA	ACTTAACAAA	GATAACTTGG	GATTCCCTGT	TTCTGACTGG	1380
TTGTTCTCAA	TGTGGCATT	TTCTCATCCT	CCACTGCTAG	AGAGACTTCA	AGCTTTGAAA	1440

ACTATGAAGC AACACTGAGA TGTCCAGGAT CTGTGACTGA AGACATTTCT GATTATTTCT 1500
 GTCCTGGCAG CATGTTCCAG CTCTTGATGT TTTTAAACTT TTTTITAGAA GAAAAATTAA 1560
 5 GTACAGAAAA GCCCAGATTT AAATACATTT AATATGTCAT TTTAAAAATG ATTTTAATAA 1620
 TTCATTTCTT AAAACACTGA ATGAATTTTG AAGCTTAATG TTTTAAAGG CATAGTTTAA 1680
 TCTTTGACAT CTAATTTTACC ATCAAGTTGT AAAATTATTT GGAAAAATAC AGAACTCGTT 1740
 TTATTTGTAT ACTTATATGG AATCTGCATG TGAGGTGTTT GAGGGCATAT GTTTGAAAAGA 1800
 10 GGGAGCATCA CCACAGGAAT CCTTCTGTG AGGTGGAAAC AGTGGTCCTG AATCATTGTG 1860
 CTCACACCTA ACTTGAAATC TGGTCTTACT TTCATGCTGT TATGATTTCA CCTGGTGAAT 1920
 CAGTGTTTTA AATAAGAAAG GTAATAGTTG GTAAGGCCAA TGTTATTTAA ATGAAAGTAG 1980
 TTAGAAAAAT GCTCTCCTAT TCTACCAAAT TTTTAATTTT TTTCTTCCCT TTCTTGCTAC 2040
 15 ACAGTGATCA AGAGTTTCTC ATAGTGCTTT GAAGTTAGAA ATTATGTATA GGATATTTTA 2100
 AATCATTGAG TTTTGTGGGG TTTTTTGTG TGTTTGTTC TTTTGTTC TGGAAAATCC 2160
 GTGTCTTTAT CTTTTTTTCC CACGTGGTAG ATATGATCCC ATTGGAGGTA AATTGTAGCT 2220
 TCTTCTCATT CATGCAGTAA ATAATACATC CTTTCACTCA GCAGAGATGG CCATATTAAA 2280
 20 CACGTTTTGC TATGTTAAAA GTGGCAGAAC AGGAAAGACG AATTAAAAAT AACATTTTTT 2340
 AAGCGACATA AGGATGAAAT ACTGATGAAT CTCTGTGACA TTACAGGGAA AAAAATATAG 2400
 TTTTCTATCT CTTTCAAGGG CAGAAGAGTT TTCATTTTAA TTTTGTAAAT TTTATCTGTA 2460
 AGTCATAAAT ATTACTTAAT CAGGCCTGAT TCTACTTTTG AAAATTACAG TTCTTGAAAT 2520
 25 GCAGATAATG TTTACTTTGA AAACAAATGT CATGAATGAT TTCCAGTTT TAAAGCTATA 2580
 TGTTTCACTG CTTTCATATCT CTGTCCACTT TCTGAATGAG AACTTATTTT GTGCCTAGAG 2640
 CTCTCACTCA CTGATAATGC TTATTACCTT CTGGGCATTT ATTCCAAAGT GGGATCAACT 2700
 GTACGCCTTT GGTATCTGAC CATAAAGTCT TTGCTCCGC TGACATTGG GTGATGTCTT 2760
 30 CACATGGAAG TATAATAAAA ATAAAAATCT AGTTTAATAC TGCATTATTT ATTTTCCTAA 2820
 GGCTAAAGAG GAGCAGTCCT ATGCTTTTAT TCAGCATCCT TTATCTGTGA CTTTCATGCTC 2880
 TGATAACTGC CTTTCCTTCC TTCTGTGCCT TTGAATACAA ATTCAGTTC TGCAAAAGTG 2940
 35 AAACATTAAA CATTGCCAAC GCAAATGT 2968

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 474 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

50 Met Gly Met Trp Ala Ser Leu Asp Ala Leu Trp Glu Met Pro Ala Glu
 1 5 10 15
 Lys Arg Ile Phe Gly Ala Val Leu Leu Phe Ser Trp Thr Val Tyr Leu
 20 25 30
 55 Trp Glu Thr Phe Leu Ala Gln Arg Gln Arg Arg Ile Tyr Lys Thr Thr

EP 0 887 416 A2

	35		40		45	
	Thr His Val Pro Pro Glu Leu Gly Gln Ile Met Asp Ser Glu Thr Phe					
5	50		55		60	
	Glu Lys Ser Arg Leu Tyr Gln Leu Asp Lys Ser Thr Phe Ser Phe Trp					
	65		70		75	80
	Ser Gly Leu Tyr Ser Glu Thr Glu Gly Thr Leu Ile Leu Leu Phe Gly					
10		85		90		95
	Gly Ile Pro Tyr Leu Trp Arg Leu Ser Gly Arg Phe Cys Gly Tyr Ala					
		100		105		110
	Gly Phe Gly Pro Glu Tyr Glu Ile Thr Gln Ser Leu Val Phe Leu Leu					
15		115		120		125
	Leu Ala Thr Leu Phe Ser Ala Leu Thr Gly Leu Pro Trp Ser Leu Tyr					
		130		135		140
	Asn Thr Phe Val Ile Glu Glu Lys His Gly Phe Asn Gln Gln Thr Leu					
20		145		150		155
	Gly Phe Phe Met Arg Asp Ala Ile Lys Lys Phe Val Val Thr Gln Cys					
		165		170		175
	Ile Leu Leu Pro Val Ser Ser Leu Leu Leu Tyr Ile Ile Lys Ile Gly					
25		180		185		190
	Gly Asp Tyr Phe Phe Ile Tyr Ala Trp Leu Phe Thr Leu Val Val Ser					
		195		200		205
	Leu Val Leu Val Thr Ile Tyr Ala Asp Tyr Ile Ala Pro Leu Phe Asp					
30		210		215		220
	Lys Phe Thr Pro Leu Pro Glu Gly Lys Leu Lys Glu Glu Ile Glu Val					
		225		230		235
	Met Ala Lys Ser Ile Asp Phe Pro Leu Thr Lys Val Tyr Val Val Glu					
35		245		250		255
	Gly Ser Lys Arg Ser Ser His Ser Asn Ala Tyr Phe Tyr Gly Phe Phe					
		260		265		270
	Lys Asn Lys Arg Ile Val Leu Phe Asp Thr Leu Leu Glu Glu Tyr Ser					
40		275		280		285
	Val Leu Asn Lys Asp Ile Gln Glu Asp Ser Gly Met Glu Pro Arg Asn					
		290		295		300
	Glu Glu Glu Gly Asn Ser Glu Glu Ile Lys Ala Lys Val Lys Asn Lys					
45		305		310		315
	Lys Gln Gly Cys Lys Asn Glu Glu Val Leu Ala Val Leu Gly His Glu					
		325		330		335
	Leu Gly His Trp Lys Trp Asp Ile Gln Ser Lys Ile Ser Leu Leu Ala					
50		340		345		350
	Arg Glu Phe Phe Pro Val Phe Phe Leu Phe Ala Val Leu Ile Gly Arg					
		355		360		365
	Lys Glu Leu Phe Ala Ala Phe Gly Phe Tyr Asp Ser Gln Pro Thr Leu					
55		370		375		380

Ile Gly Leu Leu Ile Ile Phe Gln Phe Ile Phe Ser Pro Tyr Asn Glu
 385 390 395 400
 5 Val Leu Ser Phe Cys Leu Thr Val Leu Ser Arg Arg Phe Glu Phe Gln
 405 410 415
 Ala Asp Ala Phe Ala Lys Lys Leu Gly Lys Ala Lys Asp Leu Tyr Ser
 420 425 430
 10 Ala Leu Ile Lys Leu Asn Lys Asp Asn Leu Gly Phe Pro Val Ser Asp
 435 440 445
 Trp Leu Phe Ser Met Trp His Tyr Ser His Pro Pro Leu Leu Glu Arg
 450 455 460
 15 Leu Gln Ala Leu Lys Thr Met Lys Gln His
 465 470

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2035 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

AGAAATTGAA GTAATGGCAA AGAGTATTGA CTTTCCTTTG ACGAAGGTGT ATGTTGTGGA 60
 AGGNTCTAAA CGCTCTTCCC ACAGCAATGC TTATTTTAT GGCTTCTTCA AGAACAAGCG 120
 35 AATAGTTTTG TTTGACACTC TACTAGAAGA GTACTCTGTA CTAAACAAAG ACATCCAGGA 180
 GGATTCTGGC ATGGAACCCC GCAATGAGGA AGAAGGGAAC AGTGAAGAAA TAAAAGCTAA 240
 AGTTAAAAAT AAGAAACAAG GATGTAAAAA TGAGGAGGTA CTCGCTGTAC TAGGCCATGA 300
 ACTGGGGCAC TGGAAGTTGG GACATACAGT CAAAAATATC ATTATTAGCC AGATGAATTC 360
 40 TTTCTGTGT TTTTCTTTAT TTGCTGTATT AATTGGTCGA AAGGAGCTTT TTGCTGCATT 420
 TGGTTTTTAT GATAGCCAAC CCACTCTTAT TGGACTATTG ATCATCTTCC AGTTTATTTT 480
 TTCACCTTAC AATGAGGTTT TTTCTTTTTG CCTAACAGTC CTAAGCCGCA GATTTGAGTT 540
 TCAAGCTGAT GCATTTGCCA AGAAACTTGG GAAGGCTAAA GACTTATATT CTGCTTTAAT 600
 45 CAACTTAAC AAAGATAACT TGGGATTCCC TGTTCTGAC TGGTTGTTCT CAATGTGGCA 660
 TTATTCTCAT CCTCCACTGC TAGAGAGACT TCAAGCTTTG AAAACTATGA AGCAACACTG 720
 AGATGTCCAG GATCTGTGAC TGAAGACATT TCTGATTATT TCTGTCCTGG CAGCATGTTT 780
 CAGCTCTTGA TGTTTTTAAA CTTTTTTTTT GAAGAAAAAT TAAGTACAGA AAAGCCCAGA 840
 50 TTTAAATACA TTAAATATGT CATTTTAAAA ATGATTTTAA TAATTCATTT CTTAAAACAC 900
 TGAATGAATT TTGAAGCTTA ATGTTTTTAA AGGCATAGTT TTATCTTTGA CATCTAATTT 960
 ACCATCAAGT TGTAATAATTA TTTGGAAAAA TACAGAACTC GTTTTATTTG TATACTTATA 1020
 TGAATCTGC ATGTGAGGTG TTTGAGGGCA TATGTTTGAA AGAGGGAGCA TCACCACAGG 1080
 55 AATCCCTTTC TGTGAGGTGG AAACAGTGGT CCTGAATCAT TGTGCTCACA CCTAACTTGA 1140

AATCTGGTCT TACTTTCATG CTGTTATGAT TTCACCTGGT GAATCAGTGT TTTAAATAAG 1200
 AAAGGTAATA GTTGGTAAGG CCAATGTTAT TTAAATGAAA GTAGTTAGAA AAATGCTCTC 1260
 5 CTATTCTACC AAATTTTAA TTTCTTTCTT CCCTTTCTTG CTACACAGTG ATCAAGAGTT 1320
 TCTCATAGTG CTTTGAAGTT AGAAATTATG TATAGGATAT TTTAAATCAT TGAGTTTGT 1380
 GGGGTTTTTT TGTGTTTGTG TTTCTTTTGT TTTTGGAAA ATCCGTGTCT TTATCTTTTT 1440
 TTCCCACGTG GTAGATATGA TCCCATTGGA GGTAAATTGT AGCTTCTTCT CATTTCATGCA 1500
 10 GTAAATAATA CATCCTTTCA CTCAGCAGAG ATGGCCATAT TAAACACGTT TTGCTATGTT 1560
 AAAAGTGGCA GAACAGGAAA GACGAATTAA AAATAACATT TTTTAAGCGA CATAAGGATG 1620
 AAATACTGAT GAATCTCTGT GACATTACAG GGAAAAAAT ATAGTTTCT ATCTCTTTCA 1680
 AGGGCAGAAG AGTTTTCATT TTTATTTTGT TAATTTTATC TGTAAGTCAT AAATATTACT 1740
 15 TAATCAGGCC TGATTCTACT TTTGAAAATT ACAGTTCTTG AAATGCAGAT AATGTTTACT 1800
 TTGAAAACAA ATGTCATGAA TGATTTCCAG TTTTAAAGC TATATGTTTC ACTGCTTCCA 1860
 TATCTCTGGT CCACTTTCTG GATGGAGAAC NTAATTTGGT GCCNAGAGCT CTCCTCACC 1920
 20 GATAAGGCTA ATNACCTCCG GGGCATTAT TCCAGTGGG GTCAACTGTA CGCCTTAGGG 1980
 ATCTGACCAT AAGTCTTTGG CCCGCGGAAA TTGGGGGAGG CTCCAGGGA AAANT 2035

Claims

- 30 1. An isolated polypeptide comprising an amino acid sequence which has at least 70% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of of SEQ ID NO:2.
2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity.
- 35 3. The polypeptide as claimed in claim 1 comprising the amino acid sequence of SEQ ID NO:2.
4. The isolated polypeptide of SEQ ID NO:2.
- 40 5. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 70% identity to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2; or a nucleotide sequence complementary to said isolated polynucleotide.
- 45 6. An isolated polynucleotide comprising a nucleotide sequence that has at least 70% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.
- 50 7. An isolated polynucleotide which comprises a nucleotide sequence which has at least 70% identity to that of SEQ ID NO:1 over the entire length of SEQ ID NO:1; or a nucleotide sequence complementary to said isolated polynucleotide.
8. The isolated polynucleotide as claimed in any one of claims 5 to 7 in which the identity is at least 95%.
9. An isolated polynucleotide selected from:
 - 55 (a) a polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2;
 - (b) the polynucleotide of SEQ ID NO:1; and
 - (c) a polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof; or a nucleotide sequence

complementary to said isolated polynucleotide

10. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression system is present in a compatible host cell.

11. A host cell comprising the expression system of claim 15 or a membrane thereof expressing the polypeptide of claim 1.

12. A process for producing a polypeptide of claim 1 comprising culturing a host cell of claim 11 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

13. An antibody immunospecific for the polypeptide of claim 1.

14. A method for screening to identify compounds which stimulate or which inhibit the function of the polypeptide of claim 1 which comprises a method selected from the group consisting of:

(a) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;

(b) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;

(c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide;

(d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a standard; or

(e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and said polypeptide in cells, using for instance, an ELISA assay.

15. An agonist or antagonist to the polypeptide of claims 1 to 4.

16. A compound which is:

(a) an agonist or antagonist to the polypeptide of claims 1 to 4;

(b) isolated polynucleotide of claims 5 to 9; or

(c) a nucleic acid molecule that modulates the expression of the nucleotide sequence encoding the polypeptide of claim 1;

for use in therapy.

17. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of the polypeptide of claim 1 in a subject comprising:

(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in the genome of said subject; and/or

(b) analyzing for the presence or amount of said polypeptide expression in a sample derived from said subject.

18. An isolated polynucleotide selected from the group consisting of:

(a) an isolated polynucleotide comprising a nucleotide sequence which has at least 70% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;

(b) an isolated polynucleotide comprising a nucleotide sequence which has at least 70% identity to SEQ ID NO:1 over the entire length of SEQ ID NO:3;

(c) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:3;

(d) the polynucleotide of SEQ ID NO:3; or

(e) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide which has at least 70% identity to the amino acid sequence of SEQ ID NO:4, over the entire length of SEQ ID NO:4.

19. A polypeptide selected from the group consisting of:

EP 0 887 416 A2

(a) a polypeptide which comprises an amino acid sequence which has at least 70% identity to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4;

(b) a polypeptide in which the amino acid sequence has at least 70% identity to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4;

(c) a polypeptide which comprises the amino acid of SEQ ID NO:4;

(d) a polypeptide which is the polypeptide of SEQ ID NO:4;

(e) a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

5

10

15

20

25

30

35

40

45

50

55

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 887 416 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
31.03.1999 Bulletin 1999/13

(43) Date of publication A2:
30.12.1998 Bulletin 1998/53

(21) Application number: 98304827.3

(22) Date of filing: 18.06.1998

(51) Int Cl.⁶: C12N 15/57, C12N 9/64,
C12N 1/21, C12N 5/10,
C07K 16/40, C12Q 1/37,
C12N 15/11, C12Q 1/68

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 24.06.1997 EP 97304440
12.02.1998 US 22699

(71) Applicants:
• SMITHKLINE BEECHAM CORPORATION
Philadelphia Pennsylvania 19103 (US)
• SMITHKLINE BEECHAM PLC
Brentford, Middlesex TW8 9EP (GB)

(72) Inventors:
• Kikly, Kristine, SmithKline Beecham Pharm.
King of Prussia, Pennsylvania 19406 (US)
• Knab, Anne, SmithKline Beecham Pharm.
King of Prussia, Pennsylvania 19406 (US)
• Southan, Christopher, SmithKline Beecham Plc.
Brentford, Middlesex TW8 9EP (GB)

(74) Representative: Crump, Julian Richard John et al
FJ Cleveland,
40-43 Chancery Lane
London WC2A 1JQ (GB)

(54) **Human AFC1**

(57) The hAFC1 polypeptides and polynucleotides and methods for producing such polypeptides by recom-

binant techniques are disclosed. Also disclosed are methods for utilizing hAFC1 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

EP 0 887 416 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 98 30 4827 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Rélevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	Database EMBL, Entry HSAA19855 Accession number AA210930 2 February 1997 97% identity with Seq.ID:1 nt.956-1320 98% identity with Seq.ID:3 nt.216-583 XP002091838	1-13, 16, 18, 19	C12N15/57 C12N9/64 C12N1/21 C12N5/10 C07K16/40 C12Q1/37 C12N15/11 C12Q1/68
Y	* the whole document * ---	14	
X	Database EMBL, Entry HS181310 Accession number N76181 5 April 1996 99% identity with Seq.ID:1 nt.1167-1678 99% identity with Seq.ID:3 nt.430-941 XP002091839	1-13, 16, 18, 19	
Y	* the whole document * ---	14	
X	CHEN Y. ET AL.: "Solubilization, partial purification, and affinity labeling of the membrane-bound isoprenylated protein endoprotease" BIOCHEMISTRY, vol. 35, 12 March 1996, pages 3227-3237, XP000199958	15, 16	
Y	* page 3227 * ---	14	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C12N C07K C12Q
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely:</p> <p>Claims searched incompletely: 18 19</p> <p>Claims not searched:</p> <p>Reason for the limitation of the search:</p> <p>Remark: due to the lack of data concerning Seq.ID:4, claims 18e and 19a-d are not supported by any description enabling their search.</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		1 February 1999	Macchia, G
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>	

EPO FORM 1503 03/92 (P44207)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 98 30 4827

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. CL.8)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	AKOPYAN T.N. ET AL.: "Proteolytic processing of farnesylated peptides: assay and partial purification from pig brain membranes of an endopeptidase which has the characteristics of E.C. 3.4.24.15" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 198, no. 2, 28 January 1994, pages 787-794, XP002049582	15,16	
Y	* abstract *	14	
X	Database EMBL, Entry HSZZ64182 Accession number AA359058 18 April 1997 99% identity with Seq.ID:1 nt.741-1046 100% identity with Seq.ID:3 nt.1-306 XP002091840 * the whole document *	7-9,16, 18	TECHNICAL FIELDS SEARCHED (Int. CL.8)
X	Database EMBL, Entry HSC17H011 Accession number Z43273 6 November 1994 98% identity with Seq.ID:1 nt.1079-1439 98% identity with Seq.ID:3 nt.340-702 XP002091841 * the whole document *	7-9,16, 18	
E	WO 98 54333 A (ACACIA BIOSCIENCES INC (US); ASHBY M.N.; DIMSTER-DENK D.G.; PHILIPS J.W.) 3 December 1998 * abstract * * page 47, line 9-20 * * page 67 - page 70; claims *	1-19	
	-/--		

EPO FORM 1503 03/92 (P/C10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 98 30 4827

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P, X	WO 98 05786 A (UNIVERSITY OF CALIFORNIA; RINE J.D.; BOYARTCHUK V.L.; ASHBY M.N. (US)) 12 February 1998 * page 12, line 17-20 * * page 20, line 9 - page 22, line 32 * * page 34, line 21 - page 37, line 22 * * page 54 - page 57; claims *	1-19	
A, D	BOYARTCHUK V.L. ET AL.: "Modulation of Ras and a-factor function by carboxyl-terminal proteolysis" SCIENCE, vol. 275, 21 March 1997, pages 1796-1800, XP002049583 * page 1799, right-hand column, paragraph 4 - page 1800, left-hand column, paragraph 1 *	1, 14	TECHNICAL FIELDS SEARCHED (Int.Cl.6)

EPO FORM 1503 03.02 (P04C10)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 98 30 4827

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

01-02-1999

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9854333	A	03-12-1998	NONE	
WO 9805786	A	12-02-1998	AU 4157297 A	25-02-1998

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)